Vogenx, Inc.

expected

Aug 5, 2026

status

Expected

proposed ticker

VOGX

Industry

Pharmaceutical Preparations

Headquarters

United States

Incorporated in

Exchange

NASDAQ

Price range

$11.00 – $13.00

Shares offered

6.3M shares

Offer size

$86M

Underwriters

JONESTRD

Overview

Business overview

Vogenx, Inc. is a clinical-stage biopharmaceutical company founded in 2021, focusing on the discovery and development of therapies for serious diseases related to human metabolism, specifically post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate, mizagliflozin, is a selective SGLT1 inhibitor aimed at regulating glucose absorption and postprandial dysregulation. Vogenx has advanced mizagliflozin through various clinical studies, showing promising results in reducing postprandial glucose absorption and insulin secretion, and aims to progress towards regulatory approval.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Expertise in metabolic disease drug development
Strong clinical data supporting lead product candidate
Exclusive worldwide rights to mizagliflozin (excluding Japan, Korea, Taiwan)

Risk factors

Substantial investment risks associated with drug development
Clinical trial results may not translate into regulatory approval
Dependence on the successful advancement of product candidates through clinical trials

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

Vogenx, Inc.'s offering is currently expected on NASDAQ. The expected date is Aug 5, 2026. Shares are expected to be offered at $11.00 – $13.00, with 6.3M shares on offer, for a total offer size of $86M. The proposed ticker is VOGX. Underwriters on the deal include JONESTRD. Vogenx, Inc. is headquartered in United States and incorporated in DE. It is classified under Pharmaceutical Preparations.

Vogenx, Inc. has filed 2 times, starting with a S1/A on Jul 29, 2026.

Frequently asked questions

When is Vogenx, Inc. expected to go public?

Vogenx, Inc. is expected to list on Aug 5, 2026.

What exchange will Vogenx, Inc. list on?

Vogenx, Inc. is listing on NASDAQ.

How much is Vogenx, Inc. raising in its IPO?

Vogenx, Inc.'s offering is expected to raise $86M.

What is Vogenx, Inc.'s ticker symbol?

Vogenx, Inc.'s proposed ticker is VOGX.

Where this data comes from

New York Stock Exchange listings data. Retrieved Aug 1, 2026.

View the original filing on NYSE →

All filings for this company

S1Filed Aug 1, 2026NYSEView source
S1/AFiled Jul 29, 2026SEC EDGARView source

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public filings and exchange calendars, may be incomplete or out of date, and should be verified against the original source before you act on them.